ClinicalTrials.gg
RecruitingNCT04973709Updated Oct 25, 2022

Prevalence of Dementia and Delirium in Outpatient Clinics (DESTAN Trial)

An observational study in Delirium in Old Age, Delirium Superimposed on Dementia and Delirium With Dementia, sponsored by Gulhane Training and Research Hospital. Recruiting at 1 site in Turkey. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by Gulhane Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
714
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Delirium with a site in Turkey — 11 open to participants now, 12 under way, none of them phase 3. Delirium · Turkey.

Planned enrollment
Largest of 25
714 · median 122
Started
2021
with 2 others
Observational
25 of 44
4 open now
Primary completion
2022-10
later than 0 of 11 live
Registered
9th of 44
by date
Lead sponsor
2 of 44
Gulhane Training and Research Hospital

Among the 44 studies in Delirium with a site in Turkey, this one has the largest planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2021, is one of 25 observational ones, reaches primary completion later than 0 of the 11 other live ones, and was the 9th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

11 of the 44 studies in Delirium with a site in Turkey are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Delirium with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to assess the prevalence and etiologic risk factors of delirium in outpatient geriatric patients and also hospitalized patients.

Read the detailed description

This study aimed to investigate the frequency of delirium and examines the association between delirium and other possible risk factors and prognostic factors (dementia etc.)

03

Conditions studied

  • Delirium in Old Age
  • Delirium Superimposed on Dementia
  • Delirium With Dementia

Keywords

  • Delirium
  • Dementia
  • Mortality
  • Etiology
  • Outpatient
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Community-dwelling older adults (65 years and older)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • We included all 65 years older patients who evaluated according to a comprehensive geriatric assessment that is consistently performed during admission to the outpatients' clinic of the hospital.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria were serious psychiatric disorders such as schizophrenia or major depression.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
714 participants (estimated)
Patient registry
No

Groups and cohorts

  • Delirium with dementia

    Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.

    Diagnostic Test: Confussion assessment method (CAM) · Diagnostic Test: Dementia diagnosis

  • Dementia without Delirium

    Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.

    Diagnostic Test: Dementia diagnosis

  • Delirium without Dementia

    Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.

    Diagnostic Test: Confussion assessment method (CAM)

  • No dementia, No delirium

    Delirium was detected using the short form of the Confusion Assessment Method (CAM) both at admission and daily throughout the hospital stay. Cognitive status was determined using the Mini-Mental State Exam, Clinical Dementia Rating (CDR). Dementia was defined by a CDR score of 1. The primary independent variable was a composite of delirium and dementia diagnosis, and we examined the overlap by categorizing the cases into four groups: no delirium or dementia, dementia alone, delirium alone, and DSD.

Interventions

  • Diagnostic testConfussion assessment method (CAM)

    Participants enrolled in the Delirium group according to the CAM.

  • Diagnostic testDementia diagnosis

    Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria

06

What researchers measure

Primary outcomes

  1. frequency of Mortality

    1st year mortality according to the electronic national data base

    Time frame: 1 year fellow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Oct 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2021
First posted
Jul 22, 2021
StartActual
Aug 5, 2021
Primary completionActual
Oct 5, 2022
CompletionEst.
Nov 11, 2025
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04973709
Lead sponsor
Gulhane Training and Research Hospital
Responsible party
Bilal Katipoglu (Principal investigator, Gulhane Training and Research Hospital) — Principal investigator
First posted
Jul 22, 2021
Start date
Aug 5, 2021
Primary completion
Oct 5, 2022
Completion
Nov 11, 2025 (estimated)
Last update
Oct 25, 2022

Study contacts

Bilal Katipoglu, MD
Contact
drbilal07@gmail.com
+905543330380
Mehmet Naharcı
principal investigator · Saglik Bilimleri Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion